

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM559306

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
ORBIMED ROYALTY OPPORTUNITIES II, LP		01/23/2020	Limited Partnership:
RECEIVING PARTY DATA			
Name:	PHARMING GROUP N.V.		
Street Address:	DARWINWEG 24		
Internal Address:	2333 CR		
City:	LEIDEN		
State/Country:	NETHERLANDS		
Entity Type:	Limited Liability Company: NETHERLANDS		
Name:	PHARMING TECHNOLOGIES B.V.		
Street Address:	DARWINWEG 24		
Internal Address:	2333 CR		
City:	LEIDEN		
State/Country:	NETHERLANDS		
Entity Type:	Limited Liability Company: NETHERLANDS		
Name:	PHARMING INTELLECTUAL PROPERTY B.V.		
Street Address:	DARWINWEG 24		
Internal Address:	2333 CR		
City:	LEIDEN		
State/Country:	NETHERLANDS		
Entity Type:	Limited Liability Company: NETHERLANDS		
Name:	BROEKMAN INSTITUUT B.V.		
Street Address:	DARWINWEG 24		
Internal Address:	2333 CR		
City:	LEIDEN		
State/Country:	NETHERLANDS		
Entity Type:	Limited Liability Company: NETHERLANDS		
Name:	PHARMING B.V.		
Street Address:	DARWINWEG 24		
Internal Address:	2333 CR		

CH \$115.00 85134646

City:	LEIDEN
State/Country:	NETHERLANDS
Entity Type:	Limited Liability Company: NETHERLANDS
Name:	PHARMING AMERICAS B.V.
Street Address:	DARWINWEG 24
Internal Address:	2333 CR
City:	LEIDEN
State/Country:	NETHERLANDS
Entity Type:	Limited Liability Company: NETHERLANDS
Name:	PHARMING HEALTHCARE, INC.
Street Address:	DARWINWEG 24
Internal Address:	2333 CR
City:	LEIDEN
State/Country:	NETHERLANDS
Entity Type:	Corporation: NETHERLANDS

PROPERTY NUMBERS Total: 4

Property Type	Number	Word Mark
Serial Number:	85134646	RUCONEST
Serial Number:	87093160	
Serial Number:	87093151	PHARMING
Serial Number:	87418774	

CORRESPONDENCE DATA

Fax Number: 2026626291

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (202)662-6000

Email: greed@cov.com

Correspondent Name: COVINGTON & BURLING LLP

Address Line 1: ONE CITYCENTER, 850 TENTH STREET, NW

Address Line 4: WASHINGTON, D.C. 20001

NAME OF SUBMITTER:	GENEE REED
SIGNATURE:	/Genee Reed/
DATE SIGNED:	01/28/2020

Total Attachments: 6

source=Pharming Group - IP Release - Executed#page1.tif

source=Pharming Group - IP Release - Executed#page2.tif

source=Pharming Group - IP Release - Executed#page3.tif

source=Pharming Group - IP Release - Executed#page4.tif

source=Pharming Group - IP Release - Executed#page5.tif

**RELEASE OF SECURITY INTEREST IN
INTELLECTUAL PROPERTY COLLATERAL**

This RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY, dated as of January 23, 2020 (this “**Release**”), is made by OrbiMed Royalty Opportunities II, LP, as collateral agent (in such capacity, the “**Collateral Agent**”), pursuant to (i) that certain Amended and Restated Loan and Security Agreement, dated as of May 11, 2017 (as amended, restated, amended and restated, supplemented or otherwise modified prior to the date hereof, the “**Loan and Security Agreement**”; capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed thereto in the Loan and Security Agreement), by and among Pharming Group N.V., a public limited liability company (*naamloze vennootschap*) organized and existing under the laws of the Netherlands (“**Parent**”), Pharming Healthcare, Inc., a Delaware corporation, Pharming Technologies B.V., a private company with limited liability (*besloten vennootschap met beperkte aansprakelijkheid*) incorporated under the laws of the Netherlands, Pharming Intellectual Property B.V., a private company with limited liability (*besloten vennootschap met beperkte aansprakelijkheid*) incorporated under the laws of the Netherlands (“**Pharming IP**”), Broekman Instituut B.V., a private company with limited liability (*besloten vennootschap met beperkte aansprakelijkheid*) incorporated under the laws of the Netherlands, Pharming B.V., a private company with limited liability (*besloten vennootschap met beperkte aansprakelijkheid*) incorporated under the laws of the Netherlands (“**Pharming B.V.**”), Pharming Americas B.V., a private company with limited liability (*besloten vennootschap met beperkte aansprakelijkheid*) incorporated under the laws of the Netherlands (“**Pharming Americas**” and collectively with Parent, Pharming IP and Pharming B.V., the “**Grantors**”), and OrbiMed Royalty Opportunities II, LP, as the collateral agent and lender, (ii) that certain Amended and Restated Intellectual Property Security Agreement, dated as of May 15, 2017 (the “**Parent IP SA**”), by and between Parent and the Collateral Agent, (iii) that certain Amended and Restated Intellectual Property Security Agreement, dated as of May 15, 2017 (the “**Pharming IP IP SA**”), by and between Pharming IP and the Collateral Agent, (iv) that certain Amended and Restated Intellectual Property Security Agreement, dated as of May 15, 2017 (the “**Pharming BV IP SA**”), by and between Pharming BV and the Collateral Agent, and (v) that certain Amended and Restated Intellectual Property Security Agreement, dated as of May 15, 2017 (the “**Pharming Americas IP SA**” and collectively with the Parent IP SA, the Pharming IP IP SA and the Pharming BV IP SA, the “**IP Security Agreements**”), by and between Pharming Americas and the Collateral Agent.

WITNESSETH

WHEREAS, (i) Parent executed the Parent IP SA, recorded with the U.S. Patent and Trademark Office on May 16, 2017, at Reel/Frame No. 042481/0051 (Patent), pursuant to which Parent granted to the Collateral Agent a continuing security interest in all of Parent’s right, title and interest in, to and under its Collateral constituting Intellectual Property, (ii) Pharming IP executed the Pharming IP IP SA, recorded with the U.S. Patent and Trademark Office (x) on May 18, 2017, at Reel/Frame No. 6063/0287 (Trademark) and (y) on May 16, 2017, at Reel/Frame No. 042481/0139 (Patent), pursuant to which Pharming IP granted to the Collateral Agent a continuing security interest in all of Pharming IP’s right, title and interest in, to and under its Collateral constituting Intellectual Property, (iii) Pharming BV executed the Pharming BV IP SA, recorded with the U.S. Patent and Trademark Office on May 16, 2017, at Reel/Frame No. 042481/0151 (Patent), pursuant to which Pharming BV granted to the Collateral Agent a continuing security interest in all of Pharming BV’s right, title and interest in, to and under its Collateral constituting Intellectual Property and (iv) Pharming Americas executed the Pharming Americas IP SA, recorded with the U.S. Patent and Trademark Office on May 16, 2017, at Reel/Frame No. 042481/0174 (Patent), pursuant to which Pharming Americas granted to the Collateral Agent a continuing security interest in all of Pharming Americas’ right, title and interest in, to and under its Collateral constituting Intellectual Property; and

WHEREAS, in connection with the release in full and discharge of all Obligations, the Grantors have requested that the Collateral Agent release all of its security interests in and to the Collateral.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Collateral Agent agrees as follows:

1. The Collateral Agent hereby relinquishes, terminates, discharges, cancels and releases any and all right, title and interest it may have or have acquired through the Loan and Security Agreement and the IP Security Agreements in the Collateral, including, but not limited to, the Patents and Trademarks set forth on Schedule I attached hereto and incorporated herein by reference (the “**Released Collateral**”), and re-assigns, re-conveys and re-transfers any right, title and interest that the Collateral Agent may have in the Released Collateral to the Grantors.

2. The Collateral Agent shall cause this Release to be filed with the United States Patent and Trademark Office for the purpose of recording the release of the Collateral Agent’s security interest in the Released Collateral.

3. The Collateral Agent agrees, at the request and expense of Parent, to provide the Grantors with any additional authorization necessary to effect the release of the Collateral Agent’s security interest in the Released Collateral.

[Signature Page Follows.]

IN WITNESS WHEREOF, the Collateral Agent has executed this Release of Security Interest in Intellectual Property Collateral as of the date first set forth above.

ORBIMED ROYALTY OPPORTUNITIES II, LP

By: OrbiMed ROF II, LLC,
its General Partner

By: OrbiMed Advisors LLC,
its Managing Member

By: W. Carter Neild
Name: W. Carter Neild
Title: Member

[Signature Page to Release of Security Interest in Intellectual Property Collateral]

TRADEMARK
REEL: 006848 FRAME: 0736

SCHEDULE I
to
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY COLLATERAL
Patents

Description	Patent/App. No.
Mammalian transgenesis by intracytoplasmic sperm injection	6376743
Multiplying bovine embryos	4994384
Method of cloning bovine embryos	5453366
Parthenogenic oocyte activation	5496720
In vitro activation of mammalian oocytes	6680199
Development of normal offspring from oocytes injected with freeze-dried spermatozoa	6641526
Ungulates produced by sequential nuclear transfer	6603059
Initiation of full mammalian oocyte activation by multiple sperm components	6593139
Parthenogenic oocyte activation	6194202
Parthenogenic oocyte activation	6077710
DNA sequences to target proteins to the mammary gland for efficient secretion	5565362
Genetic construct of which protein DNA comprises introns and is designed for protein production in transgenic animals	5650503
Transgenic bovine	5741957
Transgenic non-human mammal milk	5750172
Genetic construct of which protein coding DNA comprises introns and is designed for protein production in transgenic animals	5861299
Transgenic bovines and milk from transgenic bovines	6013857
Production of recombinant polypeptides by bovine species and transgenic methods	6140552
Production of heterologous protein in milk of transgenic non-human mammals comprising a construct with an intron	6548735
C1 inhibitor produced in the milk of transgenic non-human mammals	7067713
C1 inhibitor with short half-life transient treatment	RE43691
C1 inhibitor with short half-life transient treatment	7544853
Homologous recombination in mammalian cells	5612205
Homologous recombination in mammalian cells	5721367
Isolation of lactoferrin from milk	5849885
Isolation of lactoferrin from milk	5861491
Isolation of lactoferrin from milk	5919913
Method for the production of biologically active polypeptides in a mammal's milk as fusion proteins that are less active than the free polypeptides, or non-active	5959171
Production of recombinant polypeptides by bovine species and transgenic methods	6066725
Useful properties of human lactoferrin and variants thereof	6333311
Phenylalanine-free protein and DNA coding therefor	6495344
Use of C1 inhibitor for the prevention of ischemia-reperfusion injury	8071532

Peptide production	5322775
Peptide production	5366894
Peptide production	5476995
Alpha-lactalbumin gene constructs	5852224
Factor IX production in transgenic non-human mammals and factor IX DNA sequences with modified splice sites	6046380
Purification of alpha-1 proteinase inhibitor	6194553
Peptide production as fusion protein in transgenic mammal milk	6197946
Peptide production as fusion protein in transgenic mammal milk	6211427
Purification of alpha-1 proteinase inhibitor	6525176
Expression methods	6525241
Stabilization of milk from transgenic animals	7030289
Fusion proteins incorporating lysozyme	7045677
Use of anticoagulants in the production of recombinant proteins in the milk of transgenic animals	13582044
Milking device	9408366
Expression of exogenous recombinant proteins from the milk of trans-genic mammals	4873316
DNA sequences to target proteins to the mammary gland for efficient secretion	5304489
Process for the sterile filtration of milk	5576040
Method of producing a transgenic bovine or transgenic bovine embryo	5633076
Production of fibrinogen in transgenic animals	RE42704
Production of fibrinogen in transgenic animals	5639940
Parthenogenic bovine oocyte activation	5843754
Targeted synthesis of protein in mammary gland of a non-human transgenic mammal	5994616
Method of cloning bovines using reprogrammed non-embryonic bovine cells	6011197
Purification of biologically active peptides from milk	6268487
Method of producing a polypeptide in an ungulate	6395958
Transgenic animals secreting desired proteins into milk	6727405
Production of collagen in the milk of transgenic mammals	6713662
intracytoplasmic sperm injection	6376743
Lysosomal proteins produced in the milk of transgenic animals	6118045
Homologous recombination in mammal cells	5612205
Use of C1 inhibitor for the prevention of ischemia-reperfusion injury	8,415,288
Use of C1 inhibitor for the prevention of ischemia-reperfusion injury	9,211,318
Use of anticoagulants in the production of recombinant proteins in the milk of transgenic animals	9,546,381
Development of normal offspring form oocytes injected with freeze-dried spermatozoa	6,641,526
Production of human recombinant collagen in the milk of transgenic animals	5895833
Production of human recombinant collagen in the milk of transgenic animals	5962648

Production of human recombinant collagen in the milk of transgenic animals	6111165
Homologous recombination in mammalian cells	5721367
DNA sequences to target proteins	5565362
DNA sequences to target proteins	5994616
Expressions of proteins in milk	4873316
Expressions of proteins in milk	5,750,172
DNA sequences target proteins	5,304,489
Expressions of proteins in milk	5,750,172
Treatment of hereditary angioedema with C1 inhibitor	61/946,677
Treatment of hereditary angioedema with C1 inhibitor	PCT/US2015/018187
Treatment of hereditary angioedema with C1 inhibitor	15/122130

Trademarks

Description	Serial/Reg./App. No.
RUCONEST	85134646
Design Only	87093160
PHARMING	87093151
TURNING MILK INTO MEDICINE	664592
Device	87/418774